07:55 AM EST, 11/18/2024 (MT Newswires) -- Eli Lilly and Company ( LLY ) said Friday that results from a phase 3 trial of tirzepatide shows it "significantly reduced the risk of worsening heart failure" in adults with heart failure with preserved ejection fraction and obesity.

The company said both primary endpoints as well as all key secondary endpoints were met in the trial, which compared the efficacy and safety of tirzepatide to placebo.

Price: 806.02, Change: -12.91, Percent Change: -1.58